KDIGO Heat Map for CKD Prognosis
KDIGO (Kidney Disease Improving Global Outcomes) prognosis grid for CKD using GFR and albuminuria categories. Identifies low, moderate, high, and very high risk of CKD progression.
Score interpretation
KDIGO Low/Moderate risk — G1–G2 with A1–A2, or G3a with A1
→ Annual monitoring; treat modifiable risk factors (HTN, DM, proteinuria); lifestyle modification; ACEi/ARB if proteinuria; avoid nephrotoxins
KDIGO High risk — G3a/A3, G3b/A1-A2, G4/A1
→ Biannual nephrology review; RAS blockade; SGLT-2 inhibitor; consider specialist input for cause; anaemia management; bone disease screening
KDIGO Very High risk — G4–G5 with any albuminuria, or any GFR with A3
→ Quarterly nephrology review; prepare for renal replacement therapy (access creation, transplant workup); dietitian referral; phosphate and calcium management; erythropoietin therapy
Interpretation bands for the KDIGO CKD Risk. Apply clinical judgement and local guidance.
References
- KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Morphine Slow-Release (Elderly Chronic Pain) · Opioid Analgesic — Modified-Release Oral
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.